ArticleCancers2021

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis.

Ilario Giovanni Rapposelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.